Jan 26 (Reuters) - Celularity Inc CELU.O :
- CELULARITY COMPLETES STRATEGIC REVIEW OF 2023 INITIATIVES, INCLUDING ANTICIPATED BIOMATERIALS PRODUCTION RAMP-UP AND PIPELINE PRIORITIZATION OF NEXT-GENERATION PRODUCT CANDIDATES
- CELULARITY INC - COMMERCIAL BIOMATERIALS BUSINESS, DEGENERATIVE DISEASE PROGRAMS CONTINUE TO GATHER MOMENTUM
- CELULARITY - NOTIFIED SUBSTANTIAL PORTION OF WORKFORCE THAT THEIR EMPLOYMENT MAY BE IMPACTED TO ACHIEVE STRATEGIC OBJECTIVES
- CELULARITY INC - HOPEFUL THAT THERE WILL BE NO NEED TO SUBSTANTIALLY REDUCE ITS HEADCOUNT
- CELULARITY INC - PLANS TO COMPLETE REQUIRED PRECLINICAL WORK ON ITS ECM PRODUCT CANDIDATE OVER NEXT SEVERAL MONTHS
- CELULARITY INC - ALSO IS CONDUCTING PRECLINICAL WORK IN KNEE OSTEOARTHRITIS (KOA) USING ITS PLACENTA-DERIVED EXOSOMES (PEXO)
- CELULARITY - TO CONTINUE TO PARTNER WITH IMUGENE TO UTILIZE NOVEL ONCARLYTICS TECHNOLOGY TO PRIME SOLID TUMOR CELLS TO EXPRESS CD19
News: IMU Celularity Completes Strategic Review Of 2023 Initiatives
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
-0.001(1.96%) |
Mkt cap ! $367.4M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.2¢ | 5.0¢ | $627.5K | 12.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 6016291 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 460460 | 7 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |